EDCTP to grant 21.9 million euros to PAMAfrica research consortium
Category: #health  By Pankaj Singh  Date: 2020-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

EDCTP to grant 21.9 million euros to PAMAfrica research consortium

 

  • EDCTP has granted the PAMAfrica research consortium 21.9 million euros over a 5 year period while the other International research partners like MMV, Novartis, and others would contribute 22 million euros.
  • Project would include development of first new malaria treatment for infants under 5 kg, new combinations to treat drug resistant malaria, and a fast acting medicine for treatment of severe malaria.

In a recent news, the European and Developing Countries Clinical Trials Partnership, EDCTP, presented a grant of 21.9 million euros to the PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium is expected to aid the development of new medications for malaria across the vulnerable population that includes newborn infants, and patients with severe malaria drug-resistant infections. Moreover, the International research partnership would contribute a significant amount of 22 million euros making the total investment near to 44 million euros. 

It has been reported that the grant, over the period of five years, would support the development of a portfolio of projects carried out under the banner of PAMAfrica research consortium which is likely to conduct three trials to build clinical capacity and educate scientists across Africa.

As per official sources, the trials to be conducted include exploration of new combinations of compounds for the treatment of malaria in children and adults; evaluation of new generation, rapid acting treatment for severe malaria that is majorly being developed by Novartis; and testing of formulation of existing gold standard treatment artemether-lumefantrine in infants weighing less than 5kg.

Speaking on these trials, the Chief Scientific Officer of MMV and coordinator of PAMAfrica group, Dr. Timothy Wells commented that all the trials are estimated to address the areas of urgent need in the malaria treatment. The development on newborn and severe malaria is incredible in bringing treatments to this group. He further added that the support of EDCTP would not only bring together the necessary European and African clinical proficiency, but it would also support the training and development of next-gen leaders in clinical malaria research in the states of Africa.

Source credits: https://www.novartis.com/news/media-releases/international-research-partnership-and-edctp-invest-eu44m-next-generation-antimalarials-combat-drug-resistant-malaria-africa



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...